Diagnostic cut-offs, prevalence, and biochemical predictors of sarcopenia in healthy Indian adults: The Sarcopenia-Chandigarh Urban Bone Epidemiological Study (Sarco-CUBES)
- PMID: 32504420
- DOI: 10.1007/s41999-020-00332-z
Diagnostic cut-offs, prevalence, and biochemical predictors of sarcopenia in healthy Indian adults: The Sarcopenia-Chandigarh Urban Bone Epidemiological Study (Sarco-CUBES)
Abstract
Purpose: Comprehensive data on diagnosis and prevalence of sarcopenia in India are lacking. The present study was undertaken to determine cut-offs for low muscle strength (MS) and low muscle mass (MM), and find out the prevalence of sarcopenia in Indians.
Methods: Apparently healthy individuals aged ≥ 20 years with no prior history of any co-morbidities were recruited from community by door-to-door survey. Participants eligible for study underwent blood sampling. Individuals identified as having biochemical abnormalities that could potentially affect MS and MM were excluded. Enrolled participants underwent DEXA. Muscle mass, MS, and physical performance were expressed as appendicular skeletal muscle index (ASMI), dominant handgrip strength (HGS), and usual gait speed (GS), respectively. Cut-offs for low MS and MM were defined as HGS and ASMI 2SD < mean of young reference population (20-39 years). A GS ≤ 0.8 m/s defined poor physical performance. Using them, the prevalence of sarcopenia was estimated as per EWGSOP2 recommendations.
Results: After exclusion, 804 participants were enrolled (mean age = 44.4 years). Peak HGS, ASMI, and GS were achieved in the 3rd/4th decades. Muscle strength/mass was lower than Caucasians. A HGS < 27.5 kg (males)/18.0 kg (females) and an ASMI < 6.11 kg/m2 (males)/4.61 kg/m2 (females) defined low MS and MM, respectively. Accordingly, prevalence of 'probable sarcopenia', 'sarcopenia', and 'severe sarcopenia' was 14.6%, 3.2%, and 2.3%, respectively. Corresponding values were higher when European cut-offs were used. Only serum testosterone positively predicted HGS/ASMI/GS in males.
Conclusions: Indians have low MS/MM, and hence, indigenous and not Western cut-offs should be used to define sarcopenia in Indians.
Keywords: Gait speed; India; Muscle mass; Muscle strength; Sarcopenia.
Comment in
-
Validation of population-based cut-offs for low muscle mass and strength.Eur Geriatr Med. 2020 Oct;11(5):713-714. doi: 10.1007/s41999-020-00336-9. Eur Geriatr Med. 2020. PMID: 32514749 No abstract available.
Similar articles
-
Comparison of standard versus population-specific handgrip strength cut-off points in the detection of probable sarcopenia after launch of EWGSOP2.Aging Male. 2020 Dec;23(5):1564-1569. doi: 10.1080/13685538.2020.1870038. Epub 2021 Jan 12. Aging Male. 2020. PMID: 33432867
-
The prevalence of sarcopenic obesity in community-dwelling healthy Indian adults - The Sarcopenic Obesity-Chandigarh Urban Bone Epidemiological Study (SO-CUBES).Osteoporos Sarcopenia. 2021 Mar;7(1):24-29. doi: 10.1016/j.afos.2020.12.003. Epub 2021 Jan 15. Osteoporos Sarcopenia. 2021. PMID: 33869802 Free PMC article.
-
Should knee extension strength testing be implemented as a screening test for identifying probable and confirmed sarcopenia in older T2DM patients?Eur Rev Aging Phys Act. 2022 Jan 27;19(1):5. doi: 10.1186/s11556-021-00280-y. Eur Rev Aging Phys Act. 2022. PMID: 35086483 Free PMC article.
-
Risk of secondary sarcopenia in Europeans with fibromyalgia according to the EWGSOP2 guidelines: systematic review and meta-analysis.Eur J Phys Rehabil Med. 2024 Aug;60(4):703-715. doi: 10.23736/S1973-9087.24.08348-5. Epub 2024 Jun 11. Eur J Phys Rehabil Med. 2024. PMID: 38860694 Free PMC article.
-
Hand grip strength as a proposed new vital sign of health: a narrative review of evidences.J Health Popul Nutr. 2024 Jan 9;43(1):7. doi: 10.1186/s41043-024-00500-y. J Health Popul Nutr. 2024. PMID: 38195493 Free PMC article. Review.
Cited by
-
Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial.Ther Adv Endocrinol Metab. 2023 Oct 21;14:20420188231207516. doi: 10.1177/20420188231207516. eCollection 2023. Ther Adv Endocrinol Metab. 2023. PMID: 37873516 Free PMC article.
-
Diagnosing sarcopenia in clinical practice: international guidelines vs. population-specific cutoff criteria.Front Med (Lausanne). 2024 Jul 26;11:1405438. doi: 10.3389/fmed.2024.1405438. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39131085 Free PMC article. No abstract available.
-
A Pilot Case-Control Study of Muscle and Bone Health Status in Patients Who Have Recovered From COVID-19 Infection.Cureus. 2024 Dec 23;16(12):e76283. doi: 10.7759/cureus.76283. eCollection 2024 Dec. Cureus. 2024. PMID: 39850191 Free PMC article.
-
Sarcopenia and mortality in Indigenous and non-Indigenous New Zealand octogenarians-the LiLACS NZ cohort study.Eur Geriatr Med. 2025 Jun 28. doi: 10.1007/s41999-025-01261-5. Online ahead of print. Eur Geriatr Med. 2025. PMID: 40580279
-
Diabetes and Osteoporosis.Indian J Orthop. 2023 Dec 12;57(Suppl 1):209-217. doi: 10.1007/s43465-023-01049-4. eCollection 2023 Dec. Indian J Orthop. 2023. PMID: 38107797 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources